To reduce hepatic blood flow and decrease portal pressures in persons with cirrhosis, the nurse should be prepared to administer which of the following medications?
A) Bevacizumab, an angiogenesis inhibitor
B) Octreotide, a long-acting synthetic analog of somatostatin
C) Filgrastim, granulocyte colony-stimulating factor (G-CSF) analog
D) Diltiazem (Cardizem), a calcium channel blocker

Question

Quizplus · Accepted Answer

Ocetrotide, a long-acting synthetic analog of somatostatin, reduces splanchnic and hepatic blood flow and portal pressures in persons with cirrhosis. Bevacizumab was the first angiogenesis inhibitor that was shown to slow tumor growth and, more importantly, to extend the lives of patients with some cancers. Filgrastim rapidly reverses neutropenia and maintains normal ANC in patients with HIV infection. Diltiazem is used to treat a variety of conditions, such as high blood pressure, migraines, and Raynaud disease.

To Reduce Hepatic Blood Flow and Decrease Portal Pressures in Persons